At least 20 European biotechs that are developing drugs have restructured over the last five quarters - 1Q11 through 1Q12 - resulting in at least 900 layoffs. (A) Being liquidated; (B) Changed business to investment company from drug developer; (C) Cuts to be completed by mid-2013; (D) Considering